Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomasHélène Lasolle, Gérald Raverot, Rachel Desailloud et al.|European Journal of Endocrinology|2017Cited by 142
Progression of potentially aggressive pituitary neuroendocrine tumors after radiotherapy: risk factors, management, and outcomesFabio Bioletto, Guillaume Assié, Caroline Bogeat et al.|European Journal of Endocrinology|2025Cited by 3
Progression of potentially aggressive PitNETs after radiotherapy: risk factors, management, and outcomesFabio Bioletto, Guillaume Assié, Caroline Bogeat et al.|Endocrine Abstracts|2025Cited by 0